Sanofi (NYSE:SNY) announced today that it entered into an agreement to support the manufacturing and supply of the Pfizer/BioNTech COVID-19 vaccine. Pfizer and BioNTech’s vaccine is one of two to receive FDA emergency use authorization in the U.S. and it also has clearance in Europe, having received both nods in December 2020. The deal between Sanofi…
Pharma industry and Biden administration could be on a drug-pricing collision course
Prominent pharmaceutical companies including Pfizer (NYSE:PFE), Sanofi (NYSE:SNY), GlaxoSmithKline (NYSE:GSK) and Teva (NYSE: TEVA) intend to raise U.S. prices of more than 300 drugs starting Jan. 1, according to Reuters. But President-elect Joe Biden has vowed to slash drug prices. “Too many Americans cannot afford their prescription drugs, and prescription drug corporations are profiteering off of the pocketbooks of sick individuals,” he wrote in a healthcare…
Digoxin offers similar performance to the bisoprolol for AF patients with heart failure
A randomized trial published in JAMA concluded that there was no statistically significant difference in patient-reported quality of life for atrial-fibrillation (AF) patients with heart failure symptoms who took digoxin versus the beta-blocker bisoprolol (Zebeta). Digoxin was once widely used for heart failure but has become less popular after a 2015 study found patients who took the drug…
GSK, Pfizer and J&J among the most-fined drug companies, according to study
GlaxoSmithKline (LON:GSK) paid nearly $10 billion in inflation-adjusted financial penalties between January 2003 and December 2016, the highest tally for any drug company, according to research published in JAMA. That sum was more than any other in a sampling of 26 companies paying fines inside the U.S. Pfizer (NYSE: PFE) was next in line with…
Sanofi, GSK offer 20M COVID-19 vaccine doses to COVAX alliance
Sanofi (NSDQ:SNY) and GSK (LON: GSK), which have teamed up to produce a COVID-19 vaccine candidate, have signaled their intent to work with the legal administrator of the COVAX Facility. The two companies have vowed to produce 200 million doses of a vaccine based on the protein subunit AS03 adjuvant. Governments, businesses and health organizations…
Sanofi, GSK to supply up to 60 million doses of COVID-19 vaccine to UK
Sanofi (NYSE:SNY) and GlaxoSmithKline (NYSE:GSK) announced that they reached an agreement with the UK government to supply up to 60 million doses of a COVID-19 vaccine. Subject to a final contract, the UK government will receive the doses of a vaccine candidate developed by the two companies in partnership and based on the recombinant protein-based technology Sanofi used to…
GSK, Sanofi land $2.1B from feds to develop COVID-19 vaccine
The Trump administration has awarded Sanofi (NYSE:SNY) and GlaxoSmithKline (NYSE:GSK) a contract for up to $1.2 billion to develop, manufacture and deliver a vaccine for COVID-19, the companies announced today. The vaccine candidate is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established pandemic adjuvant (immunity-boosting) technology. Manufacturing will…